{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:18:26Z","timestamp":1760149106537,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The occurrence of secondary neoplasms in adult patients treated with chemotherapy in childhood is not uncommon. Prior chemotherapy is found to be an independent risk factor for the development of secondary malignancies, which are usually associated with a worse prognosis. The presented case is a 35-year-old female patient who was diagnosed with Ewing sarcoma in her late adolescence. The tumor was successfully treated with chemotherapy, but 3 years later she was diagnosed with T-cell lymphoblastic lymphoma. The patient received allogeneic hematopoietic stem cell transplantation (allo-HSCT) from human leukocyte antigen (HLA) matched related donor. The procedure was complicated by grade 2 acute graft-versus-host disease (GvHD) which resolved after implementation of immunosuppressive treatment. However, a year later, the patient developed extensive chronic GvHD (cGvHD) and required reintroduction of immunosuppressants. Prolonged immunosuppressive treatment with tacrolimus led to irreversible kidney failure. After a 2-year period of regular peritoneal dialysis, she was found to be eligible for a kidney transplant from a deceased donor. Now, 15 years after stem cell transplantation and 8 years after kidney transplantation, the patient remains in good condition overall, presenting with symptoms of limited cGvHD. The case described here presents a unique clinical scenario of a female patient who was successfully treated for her double malignancy. Moreover, she underwent effective double transplantations and was eventually found to be cured despite accompanying complications.<\/jats:p>","DOI":"10.3390\/medicina59071209","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:25:21Z","timestamp":1687911921000},"page":"1209","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Double Malignancy and Double Transplant\u2014A Bumpy Road to Success"],"prefix":"10.3390","volume":"59","author":[{"given":"Micha\u0142","family":"Razik","sequence":"first","affiliation":[{"name":"Students\u2019 Research Group, Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8541-2108","authenticated-orcid":false,"given":"Patrycja","family":"Rozwadowska","sequence":"additional","affiliation":[{"name":"Students\u2019 Research Group, Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kocl\u0119ga","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Helbig","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, Faculty of Medicine in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e26562","DOI":"10.1002\/pbc.26562","article-title":"Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience","volume":"64","author":"Friedman","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","article-title":"Association of Chemotherapy for Solid Tumors with Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era","volume":"5","author":"Morton","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1002\/cncr.25313","article-title":"Secondary hematopoietic malignancies in survivors of childhood cancer","volume":"116","author":"Rihani","year":"2010","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ijrobp.2017.11.011","article-title":"Secondary acute leukemia in sarcoma patients: A population-based study","volume":"100","author":"Sanford","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.18433\/jpps31862","article-title":"Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"24","author":"Kawashiri","year":"2021","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijrobp.2018.08.037","article-title":"Characteristics and predictors for secondary leukemia and myelodysplastic syndrome in Ewing and osteosarcoma survivors","volume":"103","author":"Sanford","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1001\/jamaoncol.2017.0465","article-title":"Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors","volume":"3","author":"Keegan","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2014-02-558833","article-title":"TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis","volume":"124","author":"Stengel","year":"2014","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.2008.07185.x","article-title":"Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD study","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/sj.bmt.1705573","article-title":"Chronic kidney disease in long-term survivors of hematopoietic cell transplant","volume":"39","author":"Hingorani","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Andronesi, A., Sorohan, B., Burcea, A., Lipan, L., Stanescu, C., Craciun, O., Stefan, L., Ranete, A., Varady, Z., and Ungureanu, O. (2022). Incidence and Risk Factors for Acute Kidney Injury after Allogeneic Stem Cell Transplantation: A Prospective Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10020262"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1053\/j.ajkd.2012.09.020","article-title":"Kidney complications of hematopoietic stem cell transplantation","volume":"61","author":"Singh","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1159\/000351648","article-title":"Calcineurin inhibitor nephrotoxicity: A review and perspective of the evidence","volume":"37","author":"Issa","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: Updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_17","first-page":"S2531-1379(22)00079-7","article-title":"Need for hemodialysis in patients undergoing hematopoietic stem cell transplantation: Risk factors and survival in a retrospective cohort","volume":"18","author":"Chapchap","year":"2022","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","volume":"388","author":"Hamadani","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: A multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e13633","DOI":"10.1111\/ctr.13633","article-title":"Amlodipine and calcineurin inhibitor-induced nephrotoxicity following allogeneic hematopoietic stem cell transplant","volume":"33","author":"Jensen","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijrobp.2011.05.081","article-title":"Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation","volume":"83","author":"Cohen","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2215\/CJN.10630917","article-title":"Changes in Glomerular Filtration Rate and Impact on Long-Term Survival among Adults after Hematopoietic Cell Transplantation: A Prospective Cohort Study","volume":"13","author":"Hingorani","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2013.52.6582","article-title":"Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation","volume":"32","author":"Chow","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13139","DOI":"10.1111\/petr.13139","article-title":"The role of continuous renal replacement therapy in the management of acute kidney injury associated with sinusoidal obstruction syndrome following hematopoietic cell transplantation","volume":"22","author":"Raina","year":"2018","journal-title":"Pediatr. Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00467-007-0672-2","article-title":"Continuous Renal Replacement Therapy (CRRT) after Stem Cell Transplantation. A Report from the Prospective Pediatric CRRT Registry Group","volume":"23","author":"Flores","year":"2008","journal-title":"Pediatric. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal Complications of Hematopoietic-Cell Transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/j.1600-6143.2010.03187.x","article-title":"Solid organ transplantation after allogeneic hematopoietic stem cell transplantation: A retrospective, multicenter study of the EBMT","volume":"10","author":"Koenecke","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","article-title":"Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: A retrospective cohort analysis from the Childhood Cancer Survivor Study","volume":"21","author":"Suh","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2169\/internalmedicine.9838-17","article-title":"An Overview of Kidney Disease Following Hematopoietic Cell Transplantation","volume":"57","author":"Ando","year":"2018","journal-title":"Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1053\/j.ajkd.2015.04.042","article-title":"Onco-nephrology: Core Curriculum 2015","volume":"66","author":"Cohen","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2021053127","DOI":"10.1542\/peds.2021-053127","article-title":"Long-term Follow-up Care for Childhood, Adolescent, and Young Adult Cancer Survivors","volume":"148","author":"Hudson","year":"2021","journal-title":"Pediatrics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00467-022-05448-x","article-title":"Acute kidney injury in pediatric hematopoietic cell transplantation: Critical appraisal and consensus","volume":"37","author":"Raina","year":"2022","journal-title":"Pediatr. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12185-010-0521-0","article-title":"Cystatin C level as a marker of renal function in allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Muto","year":"2010","journal-title":"Int. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3109\/0886022X.2015.1040699","article-title":"Urine neutrophil gelatinase associated lipocalin as an early marker of acute kidney injury in hematopoietic stem cell transplantation patients","volume":"37","author":"Sarayani","year":"2015","journal-title":"Ren. Fail."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/7\/1209\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:02:15Z","timestamp":1760126535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/7\/1209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["medicina59071209"],"URL":"https:\/\/doi.org\/10.3390\/medicina59071209","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,6,27]]}}}